Success Rate of Stem Cell Therapy for Hips: What the Research Actually Shows

Medically Reviewed by Dr. José A. Jiménez, Medical Director — Medical Doctor and Surgeon (UNAM), Specialist in Critical Care and Intensive Care Medicine, with advanced training in Stem Cell Therapy, Sports Medicine, and Musculoskeletal Ultrasound. More than 30 years of medical experience. Last Reviewed: August 2026

There is no single published success rate for stem cell therapy in hip osteoarthritis, and any clinic quoting you one specific percentage is going beyond what the evidence supports.

What the research does show is consistent: across systematic reviews, most patients receiving intra-articular mesenchymal stem cell injections report meaningful improvement in pain and function, with few adverse events. The studies also agree on the limitation — sample sizes are small, protocols vary widely between centres, and the hip is far less studied than the knee.

This article covers what the published data actually says, how to read a success rate figure critically, and which patients tend to respond best.

Get an Appointment

Complete The Form Below And We’ll Get Back To You Immediately.

Ask five clinics for a success rate and you will get five different numbers. That is not necessarily dishonesty — it reflects a genuine problem in how these studies are built.

Success is measured differently across trials. Some report pain reduction on a visual analogue scale, others use functional disability indices, others use imaging. A patient whose pain drops by half but whose scan is unchanged counts as a success under one definition and a failure under another.

Protocols also vary enormously. Cell source, cell dose, whether cells are expanded in culture, delivery method, and the use of imaging guidance all differ between studies. Two trials described as “stem cell therapy for hip osteoarthritis” may be testing meaningfully different interventions.

Finally, patient selection differs. A trial enrolling early-stage osteoarthritis will report better outcomes than one enrolling advanced degeneration, regardless of how good the therapy is.

This is why, at Renovo Clinic, we do not quote a headline percentage. Our stem cell therapy program begins with a review of your imaging and history, and an honest assessment of your specific situation.

Get an Appointment

Complete The Form Below And We’ll Get Back To You Immediately.

Why There Is No Single Success Rate

Ask five clinics for a success rate and you will get five different numbers. That is not necessarily dishonesty — it reflects a genuine problem in how these studies are built.

Success is measured differently across trials. Some report pain reduction on a visual analogue scale, others use functional disability indices, others use imaging. A patient whose pain drops by half but whose scan is unchanged counts as a success under one definition and a failure under another.

Protocols also vary enormously. Cell source, cell dose, whether cells are expanded in culture, delivery method, and the use of imaging guidance all differ between studies. Two trials described as “stem cell therapy for hip osteoarthritis” may be testing meaningfully different interventions.

Finally, patient selection differs. A trial enrolling early-stage osteoarthritis will report better outcomes than one enrolling advanced degeneration, regardless of how good the therapy is.

This is why, at Renovo Clinic, we do not quote a headline percentage. Our stem cell therapy program begins with a review of your imaging and history, and an honest assessment of your specific situation.

What the Published Research Shows

Osteoarthritis broadly. A systematic review of 43 clinical trials of mesenchymal stem cell injections for osteoarthritis found that almost all trials reported clinical improvement in the treatment group at follow-up, and roughly three-quarters reported better outcomes than the comparison group. Adipose tissue was the most common cell source. Importantly for hip patients, the knee accounted for around 95 percent of those trials — so most of this evidence base is knee data.

Hip specifically. A systematic review of MSC therapy for hip osteoarthritis reported favourable improvements in functional scores, pain relief, and radiographic findings, with minimal adverse events. The authors were equally clear about the caveat: there are few high-quality studies, outcome measures vary, and further research is needed before definitive treatment guidelines can be established.

A scoping review of stem cell-based therapies for hip osteoarthritis examined outcomes across bone marrow-derived, adipose-derived, umbilical cord-derived, and stromal vascular fraction approaches, and reached broadly similar conclusions: promising signals, meaningful methodological limitations.

The honest counterpoint. A meta-analysis published in Frontiers in Medicine examined how much of the improvement seen after MSC injection is attributable to contextual effects — patient expectation, the experience of receiving an invasive procedure, and natural symptom fluctuation — rather than to the cells themselves. It concluded that a substantial share of the observed benefit comes from these factors. We include this because you deserve the complete picture, not a selected one.

How to Read a Success Rate Figure

If a clinic gives you a percentage, four questions will tell you what it is worth.

Success by what measure? Pain reduction, functional improvement, imaging change, or avoidance of surgery are four different endpoints and will produce four different numbers.

Measured when? Results at three months and at two years often diverge considerably. Short follow-up flatters outcomes.

In which patients? A figure drawn from early-stage osteoarthritis says little about advanced hip degeneration.

Compared to what? Improvement without a control group cannot separate the treatment effect from natural variation and expectation.

A clinic willing to answer all four is giving you real information. A clinic that offers a number and changes the subject is not.

Which Hip Patients Tend to Respond Best

Across the literature and in our clinical experience, response tends to be better where the joint still has structure to work with.

Patients with mild to moderate hip osteoarthritis, where cartilage is thinned but not entirely absent, are generally the strongest candidates for stem cell therapy for hips. Patients whose dominant complaint is inflammatory pain rather than mechanical restriction also tend to do well, because reducing inflammation inside the joint capsule addresses their primary symptom directly.

Response tends to be weaker where there is complete cartilage loss, significant structural deformity, or mechanical instability. In those cases hip replacement is often the more appropriate treatment, and we say so during evaluation rather than after you have travelled.

Stem cell therapy is also generally not appropriate during active malignancy, active systemic infection, pregnancy, or with certain blood disorders. Candidacy is determined through medical evaluation.

Close-up of stem cells in a laboratory setting, highlighting regenerative medicine for hip therapy.

What About Side Effects and How Long Results Last?

Across the systematic reviews cited above, adverse events were consistently described as minimal. The most commonly reported effects are temporary: soreness at the injection site, transient swelling, and short-lived increases in joint stiffness in the days following treatment.

Duration of benefit is less well established, largely because follow-up periods in most published studies are relatively short. Studies reporting outcomes at twelve months generally show maintained improvement in responders. Longer-term data is limited, and it is not yet possible to say with confidence how many years a single treatment course sustains benefit.

What is clear is that stem cell therapy does not stop the underlying degenerative process. It is not a cure for osteoarthritis, and patients should plan on the basis that ongoing joint care matters as much as the procedure itself.

How Renovo Clinic Approaches Hip Evaluation

Every patient begins with a comprehensive evaluation. We review your medical history, current symptoms, functional limitations, and any recent imaging before making any recommendation. If you have had an X-ray or MRI within the past year, having it available makes the consultation considerably more useful.

Based on that evaluation, Dr. Jiménez develops a personalized treatment plan. Stem cell therapy is not a single fixed procedure — the protocol varies by cell dose, whether treatment is delivered into the joint alone or combined with systemic infusion, whether imaging guidance is used, and how many sessions are indicated. Those decisions follow from your diagnosis and imaging, not from a standard package.

It may also conclude that stem cell therapy is not the right option for you and that a surgical referral serves you better. We will tell you if so. For patients weighing that decision, our page on orthopedic stem cell therapy covers how regenerative treatment fits alongside conventional orthopedic care.

Renovo Clinic is located at the Plaza Toreo City Complex in Tijuana, approximately 8 minutes from the U.S. border, which makes evaluation and treatment practical for patients travelling from Southern California and beyond. Contact us to arrange a consultation.

Frequently Asked Questions

There is no single established figure. Systematic reviews of MSC therapy for hip osteoarthritis report favourable improvements in pain and function with minimal adverse events, but the authors consistently note limited high-quality studies and variation in how outcomes are measured. Any clinic quoting one specific percentage is going beyond what the published evidence supports.

The published evidence suggests it may help appropriately selected patients, particularly those with mild to moderate degeneration. It is less likely to help where cartilage is entirely absent or the joint is mechanically unstable. A medical evaluation determines which applies to you.

Studies reporting twelve-month outcomes generally show maintained improvement in patients who responded initially. Longer-term data is limited. Stem cell therapy does not halt the underlying degenerative process.

Systematic reviews consistently describe adverse events as minimal. The most common are temporary soreness at the injection site, transient swelling, and short-lived stiffness in the days after treatment.

They address different situations. Hip replacement is highly effective for advanced degeneration and remains the appropriate treatment where the joint has failed structurally. Stem cell therapy is an option earlier in the process, and it does not remove replacement as a future option.

The knee is more accessible for injection and more commonly affected, so it has attracted most of the clinical trial activity — roughly 95 percent of MSC osteoarthritis trials, according to a 43-trial systematic review. Hip-specific evidence is growing but remains smaller.

Recent Posts